These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 16084881)

  • 41. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial.
    Cheung LP; Lam PM; Lok IH; Chiu TT; Yeung SY; Tjer CC; Haines CJ
    Hum Reprod; 2005 Mar; 20(3):616-21. PubMed ID: 15608037
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Minimal stimulation using gonadotropin-releasing hormone (GnRH) antagonist and recombinant human follicle-stimulating hormone versus GnRH antagonist multiple-dose protocol in low responders undergoing in vitro fertilization/intracytoplasmic sperm injection.
    Kim CH; Kim SR; Cheon YP; Kim SH; Chae HD; Kang BM
    Fertil Steril; 2009 Dec; 92(6):2082-4. PubMed ID: 19589522
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer.
    Doldi N; Persico P; Di Sebastiano F; Marsiglio E; Ferrari A
    Gynecol Endocrinol; 2006 May; 22(5):235-8. PubMed ID: 16785142
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is inversely correlated with a mature oocyte yield and can predict "low responders".
    Ho JY; Guu HF; Yi YC; Chen MJ; Ho ES
    Fertil Steril; 2005 Apr; 83(4):883-8. PubMed ID: 15820795
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of estradiol and progesterone priming/antagonist/letrozole and microdose flare-up protocols for poor responders undergoing intracytoplasmic sperm injection.
    Yucel O; Ekin M; Cengiz H; Zebitay AG; Yalcinkaya S; Karahuseyinoglu S
    Gynecol Endocrinol; 2014 Sep; 30(9):653-6. PubMed ID: 24850255
    [TBL] [Abstract][Full Text] [Related]  

  • 46. GnRH-agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with ultrashort flare GnRH-agonist combined with multidose GnRH-antagonist protocol.
    Orvieto R; Nahum R; Zohav E; Liberty G; Anteby EY; Meltcer S
    Gynecol Endocrinol; 2013 Jan; 29(1):51-3. PubMed ID: 22857268
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.
    Berkkanoglu M; Isikoglu M; Aydin D; Ozgur K
    Fertil Steril; 2007 Sep; 88(3):665-9. PubMed ID: 17292895
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of mild stimulation and conventional stimulation in ART outcome.
    Karimzadeh MA; Ahmadi S; Oskouian H; Rahmani E
    Arch Gynecol Obstet; 2010 Apr; 281(4):741-6. PubMed ID: 19834718
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Cumulative live birth rates per oocytes retrieved cycle: evaluation of clinical outcomes of IVF/ICSI].
    Wu CX; Zhang T; Shu L; Huang J; Diao FY; Ding W; Gao Y; Wang W; Mao YD; Cui YG; Liu JY
    Zhonghua Fu Chan Ke Za Zhi; 2018 Mar; 53(3):160-166. PubMed ID: 29609229
    [No Abstract]   [Full Text] [Related]  

  • 50. GnRH agonist and antagonist protocols for stage I-II endometriosis and endometrioma in in vitro fertilization/intracytoplasmic sperm injection cycles.
    Pabuccu R; Onalan G; Kaya C
    Fertil Steril; 2007 Oct; 88(4):832-9. PubMed ID: 17428479
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Is the modified natural in vitro fertilization cycle justified in patients with "genuine" poor response to controlled ovarian hyperstimulation?
    Kedem A; Tsur A; Haas J; Yerushalmi GM; Hourvitz A; Machtinger R; Orvieto R
    Fertil Steril; 2014 Jun; 101(6):1624-8. PubMed ID: 24680364
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of r-FSH alone and in combination with r-LH.
    Levi-Setti PE; Cavagna M; Bulletti C
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):212-6. PubMed ID: 16377062
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Application of GnRH-antagonist to IVF-ET for patients with poor ovarian response].
    Wang B; Sun HX; Hu YL; Chen H; Zhang NY
    Zhonghua Nan Ke Xue; 2008 May; 14(5):423-6. PubMed ID: 18572861
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long gonadotropin-releasing hormone agonist versus short agonist versus antagonist regimens in poor responders undergoing in vitro fertilization: a randomized controlled trial.
    Sunkara SK; Coomarasamy A; Faris R; Braude P; Khalaf Y
    Fertil Steril; 2014 Jan; 101(1):147-53. PubMed ID: 24188873
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison between a GnRH antagonist and a GnRH agonist flare-up protocol in oocyte donors: a randomized clinical trial.
    Bodri D; Vernaeve V; Guillén JJ; Vidal R; Figueras F; Coll O
    Hum Reprod; 2006 Sep; 21(9):2246-51. PubMed ID: 16704995
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of mild and microdose GnRH agonist flare protocols on IVF outcome in poor responders.
    Karimzadeh MA; Mashayekhy M; Mohammadian F; Moghaddam FM
    Arch Gynecol Obstet; 2011 May; 283(5):1159-64. PubMed ID: 21221982
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization-intracytoplasmic sperm injection cycles with a gonadotropin-releasing hormone antagonist? A retrospective single-center study.
    Polyzos NP; Nelson SM; Stoop D; Nwoye M; Humaidan P; Anckaert E; Devroey P; Tournaye H
    Fertil Steril; 2013 Aug; 100(2):438-44. PubMed ID: 23602319
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of gonadotropin-releasing hormone antagonists in poor responders.
    Mahutte NG; Arici A
    Fertil Steril; 2007 Feb; 87(2):241-9. PubMed ID: 17113088
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ultrashort gonadotropin-releasing hormone agonist combined with flexible multidose gonadotropin-releasing hormone antagonist for poor responders in in vitro fertilization/embryo transfer programs.
    Orvieto R; Kruchkovich J; Rabinson J; Zohav E; Anteby EY; Meltcer S
    Fertil Steril; 2008 Jul; 90(1):228-30. PubMed ID: 17681292
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration.
    Hugues JN; Massé-Laroche E; Reboul-Marty J; Boîko O; Meynant C; Cédrin-Durnerin I
    Fertil Steril; 2011 Sep; 96(3):600-4. PubMed ID: 21880277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.